THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
It is reported that the implementation in clinical practice thrombolytic (fibrinolytic) therapy resulted inmortality reduction during firstmonth after myocardial infarction from 17-18% to 5-8%. Different details of this therapy are considered: terms of thrombolysis since the beginning of myocardial infarction, alternative methods of coronary blood flow recovery , indications and contraindications, complications and side effects, estimation of thrombolysis efficacy. Fibrin-selective and fibrin-non-selective drugs are presented. Different fibrinolytics are described: streptokinase, anistreplase, alteplase, reteplase, tenekteplase. The results of large randomized clinical trials devoted to fibrinolytic therapy of myocardial infarction are analyzed: GISSI, ISSIS, TIMI, GUSTO, INJECT, ASSENT. The possibility to increase in efficacy and safety of fibrinolytics by their combination with acetylsalicylic acid, IIb/IIIa receptor inhibitors and heparins are discussed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Рациональная фармакотерапия в кардиологии - 2(2016), 4, Seite 58-62 |
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
E. V. Konstantinova [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Alteplase |
|---|
| doi: |
10.20996/1819-6446-2006-2-4-58-62 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ041747593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ041747593 | ||
| 003 | DE-627 | ||
| 005 | 20240413191233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20996/1819-6446-2006-2-4-58-62 |2 doi | |
| 035 | |a (DE-627)DOAJ041747593 | ||
| 035 | |a (DE-599)DOAJ722abf6c62434e788706c131eac1b3f8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a E. V. Konstantinova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a It is reported that the implementation in clinical practice thrombolytic (fibrinolytic) therapy resulted inmortality reduction during firstmonth after myocardial infarction from 17-18% to 5-8%. Different details of this therapy are considered: terms of thrombolysis since the beginning of myocardial infarction, alternative methods of coronary blood flow recovery , indications and contraindications, complications and side effects, estimation of thrombolysis efficacy. Fibrin-selective and fibrin-non-selective drugs are presented. Different fibrinolytics are described: streptokinase, anistreplase, alteplase, reteplase, tenekteplase. The results of large randomized clinical trials devoted to fibrinolytic therapy of myocardial infarction are analyzed: GISSI, ISSIS, TIMI, GUSTO, INJECT, ASSENT. The possibility to increase in efficacy and safety of fibrinolytics by their combination with acetylsalicylic acid, IIb/IIIa receptor inhibitors and heparins are discussed. | ||
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a thrombolysis | |
| 650 | 4 | |a fibrinolytics | |
| 650 | 4 | |a streptokinase | |
| 650 | 4 | |a anistreplase | |
| 650 | 4 | |a alteplase | |
| 650 | 4 | |a reteplase | |
| 650 | 4 | |a tenekteplase | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a A. V. Magnitskyi |e verfasserin |4 aut | |
| 700 | 0 | |a N. A. Schostak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Рациональная фармакотерапия в кардиологии |d Столичная издательская компания, 2012 |g 2(2016), 4, Seite 58-62 |w (DE-627)DOAJ000071544 |x 22253653 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2016 |g number:4 |g pages:58-62 |
| 856 | 4 | 0 | |u https://doi.org/10.20996/1819-6446-2006-2-4-58-62 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/722abf6c62434e788706c131eac1b3f8 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.rpcardio.online/jour/article/view/1054 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1819-6446 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2225-3653 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2016 |e 4 |h 58-62 | ||